An updated indirect comparison of elranatamab versus a real-world external control arm in triple-class refractory multiple myeloma

An updated indirect comparison study, using mature MagnetisMM-3 trial data, shows elranatamab significantly improved progression-free survival, overall survival, and duration of response. Patients with triple-class refractory multiple myeloma treated with elranatamab had better clinical outcomes than those on real-world physician's choice therapies.